Global Cancer Immunotherapy Drug Discovery Outsourcing Market to grow with a CAGR of 8.70 %
Increasing healthcare infrastructure and
a supportive regulatory environment are the major drivers for the Global Cancer
Immunotherapy Drug Discovery Outsourcing Market.
According to TechSci Research report, “Global
Cancer Immunotherapy Drug Discovery Outsourcing Market Industry Size, Share, Trends, Competition, Opportunity and
Forecast, 2018-2028”, Global
Cancer Immunotherapy Drug Discovery Outsourcing Market has valued at USD 1.05
billion in 2022 and is anticipated to witness an impressive growth in the
forecast period with a CAGR of 8.70% through 2028. This can be due to
collaborations and partnerships among leading companies with a diverse approach
to merge the expertise of individual companies and to strengthen their position
in the market. Advancements in immunotherapy in the context of cancer
immunotherapy drug discovery outsourcing have been instrumental in
revolutionizing cancer treatment. These advancements are characterized by
innovative approaches, cutting-edge technologies, and a deeper understanding of
the immune system's role in cancer. Immune
checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have shown remarkable
success in treating various cancers. These drugs block the inhibitory signals
that cancer cells use to evade the immune system. Outsourcing firms have been
deeply involved in the development and testing of these therapies. Chimeric Antigen Receptor T-cell (CAR-T)
therapies involve engineering a patient's T-cells to target specific cancer
antigens. These therapies have achieved remarkable results in treating
hematological malignancies, and research is ongoing to expand their
applicability to solid tumors. Bispecific
antibodies are designed to simultaneously target cancer cells and immune cells.
They enhance the immune system's ability to recognize and destroy cancer cells,
and outsourcing firms have played a role in their development.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Cancer Immunotherapy Drug Discovery Outsourcing Market.”
In February 2023,
Personalis, Inc., a prominent player in advanced genomics for precision
oncology, has announced a new agreement with Moderna, Inc., a pioneering
biotechnology company in the field of messenger RNA (mRNA) therapeutics and
vaccines. This agreement extends the use of the Personalis NeXT Platform in
upcoming clinical studies focused on mRNA-4157/V940, an investigational
personalized cancer vaccine jointly developed by Moderna and Merck (known as
MSD outside of the United States and Canada). The NeXT Platform, previously
employed in the Phase 2b clinical study of the vaccine candidate, will continue
to be utilized. It serves the purpose of sequencing genomic data derived from a
patient's tumor sample. This sequencing is aimed at identifying the distinct
genetic mutations that are most likely to elicit a customized antitumor
response. Personalis, Inc. is at the forefront of advanced cancer genomics,
facilitating the development of the next generation of precision cancer
therapies and diagnostics. The Personalis NeXT Platform is thoughtfully
designed to adapt to the intricate and ever-evolving landscape of cancer. It
equips biopharmaceutical clients and healthcare practitioners with
comprehensive information on all approximately 20,000 human genes and the
immune system, all derived from a single sample. Adverse events and safety
concerns are a significant challenge in the Global Cancer Immunotherapy Drug
Discovery Outsourcing Market. Cancer immunotherapies work by modulating the
patient's immune system. However, this complex interaction can lead to
unintended immune-related adverse events (irAEs). Identifying and managing
these events is a challenge. Immunotherapies can produce unpredictable
responses in patients. Some individuals may experience significant side
effects, while others may respond well to the treatment. Predicting and
managing these varying responses is a challenge. Some irAEs may have a delayed
onset, appearing weeks or even months after treatment initiation. Monitoring
and managing these late-onset events require long-term follow-up and data
analysis. Immunotherapies can sometimes lead to autoimmune reactions where the
immune system attacks healthy tissues. Identifying and managing such reactions
is crucial for patient safety. Biomarkers for predicting and monitoring irAEs
are not always well-established. Developing reliable biomarkers to assess
patient safety is an ongoing challenge. The heterogeneity of patient
populations means that safety concerns can vary. Patients with different
genetic backgrounds and health conditions may have different safety profiles.
Global Cancer
Immunotherapy Drug Discovery Outsourcing Market is segmented based on Drug Type,
Service Type, Cancer Type, and by region. Based on the Drug Type, Global
Cancer Immunotherapy Drug Discovery Outsourcing Market is segmented into
Monoclonal Antibodies,
Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy, others. Oncolytic Viral Therapy is an
innovative approach within the field of cancer immunotherapy that involves
using specially engineered viruses to target and destroy cancer cells. When
applied in the context of Immunotherapy Drug Discovery Outsourcing, it means
utilizing external expertise, resources, and contract research organizations
(CROs) to research, develop, and advance oncolytic viral therapies for cancer
treatment. Oncolytic viral
therapy involves using viruses that are modified to selectively infect and
replicate within cancer cells while leaving normal, healthy cells unharmed. These
modified viruses can directly lyse (destroy) cancer cells, releasing antigens
and signals that stimulate the patient's immune system to recognize and attack
the cancer.
Based on Region, North America held the largest share
in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market. The
North American region has seen significant collaborations between
pharmaceutical companies, research institutions, and outsourcing service
providers. These partnerships drive innovation and accelerate the drug
discovery process. North America is known for its extensive clinical trial infrastructure,
making it a prime location for testing new cancer immunotherapies. This
infrastructure is essential for advancing drug development. The region's
diverse population provides a broad patient pool for clinical trials. This
diversity can be valuable in understanding the effectiveness of immunotherapies
across different demographic groups. There is a high demand for cancer
immunotherapy services in North America due to the prevalence of cancer and the
willingness of patients to explore innovative treatment options. North American
companies often collaborate with international partners and clients, extending
their reach in the global market.
Some of the major companies operating in
the Global
Cancer Immunotherapy Drug Discovery Outsourcing Market include:
- Covance, Inc.
- Horizon Discovery Group PLC
- Crown Bioscience, Inc.
- Promega Corporation
- HD Biosciences Co., Ltd.
- BPS Bioscience, Inc.
- Genscript Biotech
Corporation
- DiscoverX Corporation
- Celentyx Ltd.
- ImmunXperts SA
Download Free Sample Report
Customers can also request for 10% free
customization on this report.
“Certain
areas, particularly in North America, are projected to exert significant demand
for Cancer Immunotherapy Drug Discovery Outsourcing. The growth in the
competitive landscape and the presence of well-established companies in the
market, committed to enhance the overall wellbeing of people each year, are
expected to contribute to a remarkable growth of the Global Cancer
Immunotherapy Drug Discovery Outsourcing Market in the forecast period,"
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Cancer Immunotherapy Drug Discovery Outsourcing Market by Drug Type (Monoclonal
Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy,
others), By Service Type (Target Identification and Validation, Lead Screening
and Characterization, Cell-based Assays), by Cancer Type (Lung, Breast,
Colorectal, Melanoma, Prostate, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F has evaluated the future growth potential of Global
Cancer Immunotherapy Drug Discovery Outsourcing Market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide innovative market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Cancer Immunotherapy Drug Discovery Outsourcing Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com